Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer

NCT00471536 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00471536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00471536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Safety and Efficacy Study With the VEGF Receptor Tyrosine Kinase Inhibitor GW786034 in Patients With Metastatic Urothelial Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2008
Completion date
December 31, 2013
Enrollment
19 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

distal urethral cancer, proximal urethral cancer, recurrent bladder cancer, recurrent transitional cell cancer of the renal pelvis and ureter, recurrent urethral cancer, stage iv bladder cancer, transitional cell carcinoma of the bladder, urethral cancer associated with invasive bladder cancer